Erin M Hill-Burns1, Justine W Debelius2, James T Morton3, William T Wissemann1, Matthew R Lewis1, Zachary D Wallen1, Shyamal D Peddada4, Stewart A Factor5, Eric Molho6, Cyrus P Zabetian7, Rob Knight2,3,8, Haydeh Payami1,9. 1. Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA. 2. Department of Pediatrics, University of California San Diego, La Jolla, California, USA. 3. Department of Computer Science and Engineering, University of California San Diego, La Jolla, California, USA. 4. Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA. 5. Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA. 6. Department of Neurology, Albany Medical College, Albany, New York, USA. 7. Veterans Affairs Puget Sound Health Care System and Department of Neurology, University of Washington, Seattle, Washington, USA. 8. Center for Microbiome Innovation, University of California San Diego, La Jolla, California, USA. 9. Center for Genomic Medicine, HudsonAlpha Institute for Biotechnology, Huntsville, Alabama, USA.
Abstract
BACKGROUND: There is mounting evidence for a connection between the gut and Parkinson's disease (PD). Dysbiosis of gut microbiota could explain several features of PD. OBJECTIVE: The objective of this study was to determine if PD involves dysbiosis of gut microbiome, disentangle effects of confounders, and identify candidate taxa and functional pathways to guide research. METHODS: A total of 197 PD cases and 130 controls were studied. Microbial composition was determined by 16S rRNA gene sequencing of DNA extracted from stool. Metadata were collected on 39 potential confounders including medications, diet, gastrointestinal symptoms, and demographics. Statistical analyses were conducted while controlling for potential confounders and correcting for multiple testing. We tested differences in the overall microbial composition, taxa abundance, and functional pathways. RESULTS: Independent microbial signatures were detected for PD (P = 4E-5), participants' region of residence within the United States (P = 3E-3), age (P = 0.03), sex (P = 1E-3), and dietary fruits/vegetables (P = 0.01). Among patients, independent signals were detected for catechol-O-methyltransferase-inhibitors (P = 4E-4), anticholinergics (P = 5E-3), and possibly carbidopa/levodopa (P = 0.05). We found significantly altered abundances of the Bifidobacteriaceae, Christensenellaceae, [Tissierellaceae], Lachnospiraceae, Lactobacillaceae, Pasteurellaceae, and Verrucomicrobiaceae families. Functional predictions revealed changes in numerous pathways, including the metabolism of plant-derived compounds and xenobiotics degradation. CONCLUSION: PD is accompanied by dysbiosis of gut microbiome. Results coalesce divergent findings of prior studies, reveal altered abundance of several taxa, nominate functional pathways, and demonstrate independent effects of PD medications on the microbiome. The findings provide new leads and testable hypotheses on the pathophysiology and treatment of PD.
BACKGROUND: There is mounting evidence for a connection between the gut and Parkinson's disease (PD). Dysbiosis of gut microbiota could explain several features of PD. OBJECTIVE: The objective of this study was to determine if PD involves dysbiosis of gut microbiome, disentangle effects of confounders, and identify candidate taxa and functional pathways to guide research. METHODS: A total of 197 PD cases and 130 controls were studied. Microbial composition was determined by 16S rRNA gene sequencing of DNA extracted from stool. Metadata were collected on 39 potential confounders including medications, diet, gastrointestinal symptoms, and demographics. Statistical analyses were conducted while controlling for potential confounders and correcting for multiple testing. We tested differences in the overall microbial composition, taxa abundance, and functional pathways. RESULTS: Independent microbial signatures were detected for PD (P = 4E-5), participants' region of residence within the United States (P = 3E-3), age (P = 0.03), sex (P = 1E-3), and dietary fruits/vegetables (P = 0.01). Among patients, independent signals were detected for catechol-O-methyltransferase-inhibitors (P = 4E-4), anticholinergics (P = 5E-3), and possibly carbidopa/levodopa (P = 0.05). We found significantly altered abundances of the Bifidobacteriaceae, Christensenellaceae, [Tissierellaceae], Lachnospiraceae, Lactobacillaceae, Pasteurellaceae, and Verrucomicrobiaceae families. Functional predictions revealed changes in numerous pathways, including the metabolism of plant-derived compounds and xenobiotics degradation. CONCLUSION:PD is accompanied by dysbiosis of gut microbiome. Results coalesce divergent findings of prior studies, reveal altered abundance of several taxa, nominate functional pathways, and demonstrate independent effects of PD medications on the microbiome. The findings provide new leads and testable hypotheses on the pathophysiology and treatment of PD.
Authors: Petra Louis; Sylvia H Duncan; Sheila I McCrae; Jacqueline Millar; Michelle S Jackson; Harry J Flint Journal: J Bacteriol Date: 2004-04 Impact factor: 3.490
Authors: Timothy R Sampson; Justine W Debelius; Taren Thron; Stefan Janssen; Gauri G Shastri; Zehra Esra Ilhan; Collin Challis; Catherine E Schretter; Sandra Rocha; Viviana Gradinaru; Marie-Francoise Chesselet; Ali Keshavarzian; Kathleen M Shannon; Rosa Krajmalnik-Brown; Pernilla Wittung-Stafshede; Rob Knight; Sarkis K Mazmanian Journal: Cell Date: 2016-12-01 Impact factor: 41.582
Authors: Maria G Cersosimo; Gabriela B Raina; Cristina Pecci; Alejandro Pellene; Cristian R Calandra; Cristiam Gutiérrez; Federico E Micheli; Eduardo E Benarroch Journal: J Neurol Date: 2012-12-21 Impact factor: 4.849
Authors: Christopher B Forsyth; Kathleen M Shannon; Jeffrey H Kordower; Robin M Voigt; Maliha Shaikh; Jean A Jaglin; Jacob D Estes; Hemraj B Dodiya; Ali Keshavarzian Journal: PLoS One Date: 2011-12-01 Impact factor: 3.240
Authors: Marta Pozuelo; Suchita Panda; Alba Santiago; Sara Mendez; Anna Accarino; Javier Santos; Francisco Guarner; Fernando Azpiroz; Chaysavanh Manichanh Journal: Sci Rep Date: 2015-08-04 Impact factor: 4.379
Authors: Zachary D Wallen; Mary Appah; Marissa N Dean; Cheryl L Sesler; Stewart A Factor; Eric Molho; Cyrus P Zabetian; David G Standaert; Haydeh Payami Journal: NPJ Parkinsons Dis Date: 2020-06-12
Authors: Christopher T Fields; Timothy R Sampson; Annadora J Bruce-Keller; Drew D Kiraly; Elaine Y Hsiao; Geert J de Vries Journal: J Neurosci Date: 2018-10-31 Impact factor: 6.167
Authors: Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms Journal: Prog Brain Res Date: 2019-12-05 Impact factor: 2.453